Diagnosed Multiple Myeloma (MM) on a Phase 2 Trial Receiving Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd)

被引：0
|
作者：
Derman, Ben A. [1 ]
Kubicki, Tadeusz [2 ]
Simmons, Heidi [3 ]
Afrough, Aimaz [4 ]
Zonder, Jeffrey A. [5 ]
Grinblatt, David L. [6 ]
Anderson, Larry D., Jr. [7 ]
Kin, Andrew [8 ]
Narula, Sunil
Rayani, Shayan [1 ]
Gurbuxani, Sandeep [9 ]
Karrison, Theodore [2 ]
Jiang, Ken [2 ]
Major, Ajay [10 ]
Cooperrider, Jennifer H. [2 ]
Jacob, Allison P. [11 ]
Jakubowiak, Andrzej J. [1 ]
机构：
[1] Univ Chicago, Hematol Oncol Sect, Chicago, IL 60637 USA
[2] Univ Chicago, Chicago, IL 60637 USA
[3] Adapt Biotechnol Corp, Seattle, WA USA
[4] UT Southwestern Med Ctr, Dallas, TX USA
[5] Karmanos Canc Inst, Detroit, MI USA
[6] NorthShore Univ HealthSyst, Evanston, IL USA
[7] UT Southwestern Med Ctr, Hematol Malignancies & Cellular Therapy, Dallas, TX USA
[8] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA
[9] Univ Chicago, Dept Pathol, Chicago, IL USA
[10] Univ Colorado, Ctr Canc, Aurora, CO USA
[11] Med Affairs, Adapt Biotechnol, Seattle, WA USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-182410
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Carfilzomib, lenalidomide, and dexamethasone (KRd) versus elotuzumab and KRd in transplant-eligible patients with newly diagnosed multiple myeloma: Post-induction response and MRD results from an open-label randomized phase 3 study
    Knop, Stefan
    Stuebig, Thomas
    Kull, Miriam
    Greil, Richard
    Steiner, Normann
    Bassermann, Florian
    Nogai, Axel
    von Lilienfeld-Toal, Marie
    Janjetovic, Snjezana
    Trautmann-Grill, Karolin
    Bittrich, Max
    Engelhardt, Monika Martha
    Hoferer, Anette
    Theurich, Sebastian
    Binder, Mascha
    Zojer, Niklas
    Duerk, Heinz A.
    Brueggemann, Monika
    Held, Swantje
    Einsele, Hermann
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [22] Phase II clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone (CRd) in newly diagnosed multiple myeloma (MM) patients.
    Korde, Neha
    Zingone, Adriana
    Kwok, Mary
    Manasanch, Elisabet E.
    Bhutani, Manisha
    Costello, Rene
    Yancey, Mary Ann
    Mulquin, Marcia
    Calvo, Katherine R.
    Maric, Irina
    Tembhare, Prashant
    Yuan, Constance
    Stetler-Stevenson, Maryalice
    Arthur, Diane Carol
    Choyke, Peter L.
    Kurdziel, Karen A.
    Steinberg, Seth M.
    Raffeld, Mark
    Roschewski, Mark J.
    Landgren, Ola
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [23] AN OPEN-LABEL, PHASE 1B STUDY (MMY1001) OF DARATUMUMAB COMBINED WITH CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (KRD) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (MM)
    Usmani, S. Z.
    Chari, A.
    Lonial, S.
    Weiss, B.
    Comenzo, R. L.
    Wu, K.
    Khokhar, N. Z.
    Wang, J.
    Doshi, P.
    Jakubowiak, A.
    HAEMATOLOGICA, 2017, 102 : 269 - 269
  • [24] Comparative efficacy of carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) in newly-diagnosed multiple myeloma: A systematic review and meta-analysis
    Costa, Bruno Almeida
    Costa, Thomaz Alexandre
    Pak, Kevin
    Patel, Aesha
    Felix, Nicole
    Mouhieddine, Tarek H.
    Richter, Joshua
    AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (07) : 1411 - 1414
  • [25] Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant
    Derman, Benjamin A.
    Cooperrider, Jennifer
    Rosenblatt, Jacalyn
    Avigan, David E.
    Rampurwala, Murtuza
    Barnidge, David
    Major, Ajay
    Karrison, Theodore
    Jiang, Ken
    Ramsland, Aubrianna
    Kubicki, Tadeusz
    Jakubowiak, Andrzej J.
    BLOOD CANCER JOURNAL, 2024, 14 (01):
  • [26] Results of a Phase 1 Clinical Trial of Belantamab Mafadotin (BelMaf) Combined With Carfilzomib, Lenalidomide, and Dexamethasone (KRd) for Multiple Myeloma (MM) After One Prior Line of Therapy (LOT)
    Atrash, Shebli
    Symanowski, James
    Norek, Sarah
    Plott, Monica
    Cox, Robin
    Flynn, Cecilia
    Bumgarner, Kelly
    Rhinehardt, Darynne
    Begic, Xhevahire
    Friend, Reed
    Paul, Barry
    Varga, Cindy
    Ferreri, Christopher
    Pineda-Roman, Mauricio
    Bhutani, Manisha
    Voorhees, Peter M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S36 - S36
  • [27] MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma
    Bhutani, Manisha
    Robinson, Myra
    Foureau, David
    Atrash, Shebli
    Paul, Barry
    Guo, Fei
    Grayson, Jason M.
    Ivanina-Foureau, Anna
    Pineda-Roman, Mauricio
    Varga, Cindy
    Friend, Reed
    Ferreri, Christopher J.
    Begic, Xhevahire
    Norek, Sarah
    Drennan, Tiffany
    Anderson, Michelle B.
    Symanowski, James T.
    Voorhees, Peter M.
    Usmani, Saad Z.
    BLOOD ADVANCES, 2025, 9 (03) : 507 - 519
  • [28] Carfilzomib, lenalidomide and dexamethasone (KRd) versus elotuzumab-KRd as induction and consolidation in transplant-eligible patients with newly diagnosed multiple myeloma: post-induction IMWG and MRD response of a randomized multicenter study
    Knop, S.
    Kull, M.
    Kroenke, J.
    Drewniok, P.
    Schaefer-Eckart, K.
    von, Metzler I.
    Wolleschak, D.
    Kimmig, C.
    Greiner, J.
    Boettcher, S.
    Dechow, T.
    Hentrich, M.
    Khandanpour, C.
    Shumilov, E.
    Naumann, R.
    Seggewiss-Bernhardt, R.
    Hackanson, B.
    Wang, S. -Y.
    Salwender, H.
    Sormann, S.
    Stuebig, T.
    Brueggemann, M.
    Einsele, H.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 58 - 59
  • [29] Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
    Jakubowiak, Andrzej
    Usmani, Saad Z.
    Krishnan, Amrita
    Lonial, Sagar
    Comenzo, Raymond L.
    Wang, Jianping
    de Boer, Carla
    Deraedt, William
    Weiss, Brendan M.
    Schecter, Jordan M.
    Chari, Ajai
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (10): : 701 - 710
  • [30] Panobinostat plus lenalidomide and dexamethasone phase I trial in multiple myeloma (MM)
    Spencer, A.
    Taylor, K.
    Lonial, S.
    Mateos, M. V.
    Jalaluddin, M.
    Hazell, K.
    Bourquelot, P. M.
    San Miguel, J. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345